- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07426757
En öppen studie för att utvärdera PF-07994525 hos deltagare med avancerad cancer
En öppen fas 1-studie för att utvärdera PF-07994525 hos deltagare med avancerade maligniteter
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-post: ClinicalTrials.gov_Inquiries@pfizer.com
Studieorter
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80218
- Rekrytering
- Colorado Blood Cancer Institute
-
Denver, Colorado, Förenta staterna, 80218
- Rekrytering
- Presbyterian/St. Luke's Medical Center
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06511
- Rekrytering
- Smilow Cancer Hospital Phase 1 Unit
-
New Haven, Connecticut, Förenta staterna, 06510
- Rekrytering
- Yale-New Haven Hospital-Yale Cancer Center
-
New Haven, Connecticut, Förenta staterna, 06510
- Rekrytering
- Smilow Cancer Hospital - Yale New Haven Health
-
New Haven, Connecticut, Förenta staterna, 06511
- Rekrytering
- Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
-
North Haven, Connecticut, Förenta staterna, 06473
- Rekrytering
- Smilow Cancer Hospital - North Haven
-
-
Florida
-
Coral Gables, Florida, Förenta staterna, 33146
- Rekrytering
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
-
Coral Springs, Florida, Förenta staterna, 33065
- Rekrytering
- Sylvester Comprehensive Cancer Center - Coral Springs
-
Deerfield Beach, Florida, Förenta staterna, 33442
- Rekrytering
- University of Miami Hospital and Clinics - Deerfield Beach
-
Doral, Florida, Förenta staterna, 33166
- Rekrytering
- Sylvester Comprehensive Cancer Center- Doral
-
Hollywood, Florida, Förenta staterna, 33021
- Rekrytering
- Sylvester Comprehensive Cancer Center - Hollywood
-
Miami, Florida, Förenta staterna, 33136
- Rekrytering
- Sylvester Comprehensive Cancer Center
-
Miami, Florida, Förenta staterna, 33136
- Rekrytering
- University of Miami Hospital and Clinics
-
Miami, Florida, Förenta staterna, 33176
- Rekrytering
- Sylvester Comprehensive Cancer Center- Kendall
-
North Miami, Florida, Förenta staterna, 33181
- Rekrytering
- Sylvester Comprehensive Cancer Center - Sole Mia
-
Plantation, Florida, Förenta staterna, 33324
- Rekrytering
- Sylvester Comprehensive Cancer Center - Plantation
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30308
- Rekrytering
- Emory University Hospital Midtown
-
Atlanta, Georgia, Förenta staterna, 30322
- Rekrytering
- Emory University Hospital
-
Atlanta, Georgia, Förenta staterna, 30322
- Rekrytering
- Winship Cancer Institute, Emory University
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43210
- Rekrytering
- The James Cancer Hospital and Solove Research Institute
-
Columbus, Ohio, Förenta staterna, 43210
- Rekrytering
- Ohio State University Hospitals
-
Columbus, Ohio, Förenta staterna, 43210
- Rekrytering
- The James Outpatient Care West Campus
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- Tristar BMT
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- SCRI Oncology Partners
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- TriStar Centennial Medical center
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 5G2
- Rekrytering
- Arthur J.E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8V 5C2
- Har inte rekryterat ännu
- Juravinski Cancer Centre
-
Toronto, Ontario, Kanada, M5G2M9
- Rekrytering
- University Health Network- Princess Margaret Cancer Centre
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
- Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)
Measurable disease based on IMWG criteria as defined by at least 1 of the following:
-
Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
-
Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
-
Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
- Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion Criteria:
- Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
- Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
- Active or suspected cerebral/meningeal disease related to the underlying malignancy.
- Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part 1
Monotherapy Dose Expansion |
Oral administration Oral administration |
|
Experimentell: Part 2
Monotherapy Dose Escalation |
Oral administration |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Type, incidence and severity of participants with adverse events (AEs)
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), timing, seriousness, and relatedness of adverse events (AEs) |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Type, incidence and severity of participants with laboratory abnormalities
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Number of participants with dose modifications
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Tidsram: Baseline to end of DLT evaluation period
|
Occurrence of DLTs as defined by the protocol |
Baseline to end of DLT evaluation period
|
|
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 2: Recommended Dose for future development
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Safety, and preliminary anti-tumor activity |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objektivt svarstakt (ORR) enligt International Myeloma Working Groups (IMWG) svarskriterier som fastställts av utredaren.
Tidsram: Baslinje till datumet för den första dokumentationen av sjukdomsförlopp, död eller start av ny antikancerbehandling (ungefär 2 år)
|
Baslinje till datumet för den första dokumentationen av sjukdomsförlopp, död eller start av ny antikancerbehandling (ungefär 2 år)
|
|
|
Komplett responsfrekvens (CRR) enligt International Myeloma Working Group (IMWG) responskriterier som fastställts av undersökaren.
Tidsram: Baslinje till datumet för den första dokumentationen av sjukdomsframsteg, död, eller påbörjad ny antikancerterapi (ungefär 2 år)
|
Baslinje till datumet för den första dokumentationen av sjukdomsframsteg, död, eller påbörjad ny antikancerterapi (ungefär 2 år)
|
|
|
Tid till respons (TTR) per IMWG som bestäms av utredaren
Tidsram: Baslinje till datum för första dokumentationen av sjukdomsprogression, dödsfall eller påbörjande av ny antikancerterapi (cirka 2 år)
|
Baslinje till datum för första dokumentationen av sjukdomsprogression, dödsfall eller påbörjande av ny antikancerterapi (cirka 2 år)
|
|
|
Varaktighet av respons (DOR) per IMWG som fastställts av undersökaren
Tidsram: Baslinje till datumet för den första dokumentationen av sjukdomsframsteg, död eller start av ny antikancerbehandling (ungefär 2 år)
|
Baslinje till datumet för den första dokumentationen av sjukdomsframsteg, död eller start av ny antikancerbehandling (ungefär 2 år)
|
|
|
Varaktighet av komplett respons (DOCR) enligt IMWG som bestäms av utredaren
Tidsram: Baseline tills datumet för den första dokumentationen av sjukdomsframsteg, död eller start av ny anticancertherapi (cirka 2 år)
|
Baseline tills datumet för den första dokumentationen av sjukdomsframsteg, död eller start av ny anticancertherapi (cirka 2 år)
|
|
|
Progressionsfri överlevnad (PFS) per IMWG som fastställts av utredaren
Tidsram: Baslinje till datum för den första dokumentationen av sjukdomsframsteg, död eller start av ny antikancerbehandling (ungefär 2 år)
|
Baslinje till datum för den första dokumentationen av sjukdomsframsteg, död eller start av ny antikancerbehandling (ungefär 2 år)
|
|
|
Överlevnad totalt (OS)
Tidsram: Baslinje till datum för första dokumentation av sjukdomsprogression, död eller start av ny antikancerbehandling (ungefär 2 år)
|
Baslinje till datum för första dokumentation av sjukdomsprogression, död eller start av ny antikancerbehandling (ungefär 2 år)
|
|
|
Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Cmin as data permit
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Accumulation ratio (Rac) as data permit
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
AUC from time zero to time of last measurable concentration (AUClast)
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Time to Maximum concentration (Tmax)
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Maximum Observed Concentration (Cmax)
Tidsram: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Pfizer CT.gov Call Center, Pfizer
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- C6331001
- KAT2i (Annan identifierare: Alias Study Number)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .